WebMay 20, 2024 · Star 0. This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon. Generic Name. Branaplam. DrugBank Accession Number. DB14918. Background. Branaplam is under investigation in clinical trial NCT02268552 (An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)). WebAug 25, 2024 · Branaplam : VIBRANT-HD Study Update. Aug 25, 2024. Novartis has temporarily suspended dosing of study drug in the Ph2b VIBRANT-HD trial of branaplam …
RNA-Targeted Therapies and High-Throughput …
WebOct 28, 2024 · Branaplam is a therapeutic agent currently in clinical development for the treatment of infants with type 1 spinal muscular atrophy (SMA). Since preclinical studies showed that branaplam had cell-cycle arrest effects, we sought to determine whether branaplam may affect postnatal cerebellar development and brain neurogenesis. WebNovartis shares disappointing update from the VIBRANT-HD trial of branaplam This afternoon, Novartis shared with HD community organizations that dosing in the VIBRANT-HD trial of the huntingtin-lowering drug branaplam has been temporarily suspended. This decision was made based on the recommendation of an independent Data Monitoring … nutcracker theatre
Dosing of Branaplam in Huntington
WebBranaplam (LMI070; NVS-SM1) is a highly potent, selective and orally active survival motor neuron-2 (SMN2) splicing modulator with an EC50 of 20 nM for SMN. Branaplam inhibits human-ether-a-go-go-related gene (hERG) with an IC50 of 6.3 μM. Branaplam elevates full-length SMN protein and extends survival in a severe spinal muscular atrophy (SMA ... WebFeb 1, 2024 · With branaplam officially sidelined, the slim crop of Huntington’s drugs in advanced testing becomes even slimmer. Sage Therapeutics is currently running a trio … WebJul 26, 2024 · Novartis is stopping the clinical development of branaplam (LMI070), its experimental oral treatment for spinal muscular atrophy (SMA) being evaluated in a … non reverse thunderbird bass pickguard